Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Previously Treated Non-Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00045006
What this trial is testing

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

Who this might be right for
Cancer
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT00228358
What this trial is testing

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Who this might be right for
HER2-positive Breast CancerRecurrent Breast CancerRecurrent Non-small Cell Lung Cancer+6 more
University of Washington 8
Testing effectiveness (Phase 2)WithdrawnNCT06555263
What this trial is testing

Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Lung CancerLung Cancer MetastaticLung Cancer, Nonsmall Cell+3 more
Sutro Biopharma, Inc.
Early research (Phase 1)Study completedNCT02182102
What this trial is testing

Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 26
Testing effectiveness (Phase 2)UnknownNCT02504346
What this trial is testing

AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies

Who this might be right for
Lung CancerTargeted Therapy
Oslo University Hospital 200
Testing effectiveness (Phase 2)Looking for participantsNCT07659782
What this trial is testing

VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Verastem, Inc. 105
Testing effectiveness (Phase 2)Study completedNCT03023423
What this trial is testing

Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 100
Testing effectiveness (Phase 2)Study completedNCT00452244
What this trial is testing

Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Lung Cancer
National Cancer Center, Korea 110
Testing effectiveness (Phase 2)UnknownNCT04878107
What this trial is testing

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy

Who this might be right for
Non-Small Cell Lung Cancer
Wuhan University 88
Large-scale testing (Phase 3)Active Not RecruitingNCT05096663
What this trial is testing

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Who this might be right for
Advanced Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+6 more
SWOG Cancer Research Network 82
Testing effectiveness (Phase 2)Study completedNCT03184571
What this trial is testing

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Lung Cancer MetastaticNSCLC Stage IVAdenocarcinoma of Lung
BerGenBio ASA 99
Testing effectiveness (Phase 2)Study completedNCT01465802
What this trial is testing

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
Pfizer 236
Testing effectiveness (Phase 2)WithdrawnNCT02673814
What this trial is testing

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Peregrine Pharmaceuticals
Testing effectiveness (Phase 2)UnknownNCT04063462
What this trial is testing

Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 60
Early research (Phase 1)Study completedNCT03607188
What this trial is testing

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 17
Early research (Phase 1)Study completedNCT00327288
What this trial is testing

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

Who this might be right for
Non-small Cell Lung CancerBreast CancerProstate Cancer
AmpliMed Corporation 34
Not applicableStudy completedNCT01004601
What this trial is testing

Low Dose Weekly Docetaxel Versus Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Chang Gung Memorial Hospital 179
Large-scale testing (Phase 3)Not Yet RecruitingNCT07442565
What this trial is testing

SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

Who this might be right for
Non-Small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 506
Testing effectiveness (Phase 2)Active Not RecruitingNCT04625647
What this trial is testing

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Who this might be right for
Lung AdenocarcinomaLung Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell Carcinoma+3 more
SWOG Cancer Research Network 116
Testing effectiveness (Phase 2)Study completedNCT00400829
What this trial is testing

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI) 66
Next Page